Shares of MapLight Therapeutics (MPLT) closed 73% lower on Monday after the biotech reported mixed results from a mid-stage trial of its experimental schizophrenia drug.The drop erased more than $1 billion in market value, leaving the company’s valuation around $449 million after the selloff.Mixed…
The phase II ZEPHYR study of ML-007C-MA in schizophrenia met its primary endpoint, showing significant efficacy on PANSS and cognitive measures, with a favorable safety and tolerability profile. The cognitive benefit appears independent of antipsychotic effects, supporting further pivotal studies a…
The phase II ZEPHYR study of ML-007C-MA in schizophrenia met its primary endpoint, showing significant improvements in psychotic symptoms and cognition with a favorable safety profile. The BID dose demonstrated robust efficacy and tolerability, supporting advancement to pivotal studies and potentia…
